Triflusal

Triflusal

Chemical structure of Triflusal

Triflusal is a pharmaceutical drug that belongs to the class of antiplatelet agents. It is primarily used in the prevention of thromboembolic disorders, such as stroke and myocardial infarction. Triflusal is chemically related to aspirin, but it has a distinct mechanism of action and pharmacokinetic profile.

Mechanism of Action

Triflusal works by inhibiting the enzyme cyclooxygenase (COX), which is crucial in the synthesis of thromboxane A2, a potent inducer of platelet aggregation. Unlike aspirin, triflusal also increases the levels of nitric oxide and prostacyclin, both of which have vasodilatory and antiplatelet effects. This dual action contributes to its effectiveness in preventing blood clots.

Pharmacokinetics

Triflusal is administered orally and is rapidly absorbed from the gastrointestinal tract. It is metabolized in the liver to its active metabolite, 2-hydroxy-4-trifluoromethylbenzoic acid (HTB), which is responsible for most of its antiplatelet activity. The drug and its metabolites are excreted primarily through the kidneys.

Clinical Uses

Triflusal is indicated for the prevention of thromboembolic events in patients with a history of transient ischemic attacks (TIAs) or ischemic stroke. It is also used in patients with coronary artery disease to reduce the risk of myocardial infarction.

Side Effects

Common side effects of triflusal include gastrointestinal disturbances, such as nausea, vomiting, and dyspepsia. Unlike aspirin, triflusal has a lower risk of causing gastrointestinal bleeding. Other side effects may include headache, dizziness, and allergic reactions.

Contraindications

Triflusal is contraindicated in patients with known hypersensitivity to the drug or its components. It should be used with caution in patients with renal impairment or hepatic impairment.

Related Pages

• Aspirin
• Antiplatelet drug
• Thromboembolism
• Stroke
• Myocardial infarction